Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02175004 · ClinicalTrials.gov registry record · Phase 3
Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
A Phase 3 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 135
- Enrollment target
NCT02175004 is a Phase 3 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 135 participants.
The verdict
NCT02175004, a Phase 3 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 135 participants
- Enrollment target
Study Summary
This study evaluates the safety and tolerability of extended dosing with IONIS-TTR Rx in patients with Familial Amyloid Polyneuropathy.
Interventions
- DRUG Inotersen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2014-06-26 |
| Est. Completion | 2021-01-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02175004
The ClinicalTrials.gov registry entry for NCT02175004 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inotersen is the first listed.
NCT02175004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02175004 about?
NCT02175004 is a clinical study titled "Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)". This study evaluates the safety and tolerability of extended dosing with IONIS-TTR Rx in patients with Familial Amyloid Polyneuropathy.
What is the current status of trial NCT02175004?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 135 participants. The study started on 2014-06-26. Estimated completion is 2021-01-07.
What interventions are being tested in trial NCT02175004?
The interventions under investigation include: Inotersen (DRUG).
Who is sponsoring clinical trial NCT02175004?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.